Kyntra Bio (MEX:KYNB) Cyclically Adjusted Revenue per Share: MXN754.48 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:KYNB Kyntra Bio Inc MEX:KYNB
54 GF Score
Price MXN119.00
GF Value MXN85.02
! 8 Warning Signs
View Full Analysis

What is Kyntra Bio Cyclically Adjusted Revenue per Share?

Kyntra Bio MEX:KYNB -6.96% 54 Cyclically Adjusted Revenue per Share is MXN754.48 as of Jun. 2026. GuruFocus rates MEX:KYNB with a GF Score™ of 54/100 and a GF Value™ of MXN85.02. The stock has 8 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Kyntra Bio's adjusted revenue per share for the three months ended in Jun. 2026 was MXN-6.354. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is MXN754.48 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Kyntra Bio's average Cyclically Adjusted Revenue Growth Rate was -12.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-08-19), Kyntra Bio's current stock price is MXN119.00. Kyntra Bio's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was MXN754.48. Kyntra Bio's Cyclically Adjusted PS Ratio of today is 0.16.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Kyntra Bio was 7.00. The lowest was 0.09. And the median was 0.19.


Kyntra Bio  (MEX:KYNB) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Kyntra Bio's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=119.00/754.48
=0.16

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Kyntra Bio was 7.00. The lowest was 0.09. And the median was 0.19.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Kyntra Bio Cyclically Adjusted Revenue per Share Related Terms


Kyntra Bio Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Kyntra Bio's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kyntra Bio Cyclically Adjusted Revenue per Share Chart

Kyntra Bio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 1,134.53 1,355.69 926.47

Kyntra Bio Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,128.99 968.72 926.47 920.28 754.48

MEX:KYNB vs ACTU, PLRZ, IGC: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Kyntra Bio's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kyntra Bio Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kyntra Bio's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Kyntra Bio's Cyclically Adjusted PS Ratio falls into.


MEX:KYNB
54GF Score
Kyntra Bio Inc MEX:KYNB
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kyntra Bio Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Kyntra Bio's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-6.354/333.9520*333.9520
=-6.354

Current CPI (Jun. 2026) = 333.9520.

Kyntra Bio Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 231.518 241.428 320.244
201612 289.028 241.432 399.787
201703 216.463 243.801 296.505
201706 196.383 244.955 267.733
201709 242.392 246.819 327.962
201712 183.477 246.524 248.546
201803 174.963 249.554 234.135
201806 257.801 251.989 341.654
201809 160.636 252.439 212.506
201812 623.284 251.233 828.502
201903 135.033 254.202 177.396
201906 1,002.936 256.143 1,307.600
201909 188.196 256.759 244.776
201912 43.042 256.974 55.935
202003 162.129 258.115 209.764
202006 276.676 257.797 358.408
202009 259.597 260.280 333.076
202012 354.527 260.474 454.537
202103 214.157 264.877 270.005
202106 131.398 271.696 161.506
202109 863.986 274.310 1,051.839
202112 91.448 278.802 109.537
202203 325.397 287.504 377.967
202206 160.374 296.311 180.747
202209 84.380 296.808 94.940
202212 178.149 296.797 200.451
202303 172.070 301.836 190.379
202306 194.372 305.109 212.747
202309 177.885 307.789 193.006
202312 -317.991 306.746 -346.194
202403 106.327 312.332 113.687
202406 4.579 314.175 4.867
202409 0.602 315.301 0.638
202412 16.204 315.605 17.146
202503 13.877 319.799 14.491
202506 6.280 322.561 6.502
202509 4.881 324.800 5.019
202512 5.683 324.054 5.857
202603 16.656 330.213 16.845
202606 -6.354 333.952 -6.354

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of MXN754.48 mean?
Kyntra Bio (MEX:KYNB) has a Cyclically Adjusted Revenue per Share of MXN754.48 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Kyntra Bio and its competitors.
Is Kyntra Bio's Cyclically Adjusted Revenue per Share too high?
Kyntra Bio's current Cyclically Adjusted Revenue per Share is MXN754.48. Overall, Kyntra Bio has a GF Score™ of 54/100, reflecting its overall financial health beyond just this single metric.
How does Kyntra Bio's Cyclically Adjusted Revenue per Share compare to ACTU and PLRZ?
Kyntra Bio's Cyclically Adjusted Revenue per Share of MXN754.48 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Kyntra Bio and its competitors. Kyntra Bio's current Cyclically Adjusted Revenue per Share is MXN754.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kyntra Bio stock overvalued right now?
Kyntra Bio (MEX:KYNB) has a current Cyclically Adjusted Revenue per Share of MXN754.48. The stock's GF Value™ is MXN85.02, compared to a current price of MXN119.00 — trading 40% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is MXN754.48. Kyntra Bio's overall GF Score™ is 54/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Kyntra Bio (MEX:KYNB), the current Cyclically Adjusted Revenue per Share is MXN754.48 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Kyntra Bio (MEX:KYNB) Overvalued in 2026?

Based on GuruFocus' analysis, Kyntra Bio stock appears to be overvalued. The current stock price of MXN119.00 is trading 40% above its estimated GF Value™ of MXN85.02.

Key valuation signals for MEX:KYNB:

  • Cyclically Adjusted Revenue per Share: MXN754.48
  • GF Value™: MXN85.02 vs. price of MXN119.00 (40% above fair value)
  • GF Score™: 54/100 with 8 warning signs

No single metric tells the full story. See the MEX:KYNB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Kyntra Bio Business Description

Other Exchanges KYNB:USA0IL8:UK1FG0:Germany
Address 350 Bay Street, Suite 100, No. 6009, San Francisco, CA, USA, 94133
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.
54GF Score

Get the complete analysis for MEX:KYNB

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN119.00
Price
MXN85.02
GF Value